View Filing Data

Document and Entity Information - shares	6 Months Ended
Jun. 30, 2018	Jul. 31, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Trading Symbol	MGTX
Entity Registrant Name	MeiraGTx Holdings plc
Entity Central Index Key	0001735438
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		27,184,132

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 102,060,551	$ 8,548,638
Prepaid expenses	1,613,955	1,961,243
Other current assets	311,283	965,233
Total Current Assets	103,985,789	11,475,114
Property and equipment, net	13,567,806	14,255,729
Restricted cash	123,376	123,376
TOTAL ASSETS	117,676,971	25,854,219
CURRENT LIABILITIES:
Accounts payable	3,461,441	7,055,380
Accrued expenses	5,289,261	9,332,944
Note payable		1,442,009
Warrant liability		2,679,633
Capitalized lease obligation-current portion	28,715	30,850
Due to Kadmon	0	861,030
Total Current Liabilities	8,779,417	21,401,846
Capitalized lease obligation	20,732	34,298
Deferred rent	224,367	266,290
Other liabilities	180,350	178,419
TOTAL LIABILITIES	9,204,866	21,880,853
COMMITMENTS
Convertible Preferred C Shares 0 and 5,005,935 outstanding at June 30, 2018 December 31, 2017, respectively (liquidation preference of $52,455,700 at December 31, 2017)		51,338,631
SHAREHOLDERS' EQUITY (DEFICIT):
A Ordinary Shares, $0.00003881 nominal value 27,184,132 issued and outstanding at June 30, 2018 8,826,190 issued and 8,714,563 issued and outstanding at December 31, 2017	1,055	342
Capital in excess of nominal value	221,080,313	20,080,713
Accumulated other comprehensive loss	(801,235)	(2,022,477)
Accumulated deficit	(111,808,028)	(65,423,843)
Total Shareholders' Equity (Deficit)	108,472,105	(47,365,265)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT)	$ 117,676,971	$ 25,854,219

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating expenses:
General and administrative	$ 17,378,052	$ 2,221,896	$ 28,500,068	$ 4,370,436
Research and development	7,790,694	5,363,545	14,718,016	10,186,902
Total operating expenses	25,168,746	7,585,441	43,218,084	14,557,338
Loss from operations	(25,168,746)	(7,585,441)	(43,218,084)	(14,557,338)
Other non-operating income (expense):
Other income	83,075		83,075
Foreign currency (loss) gain	(2,726,624)	449,625	(1,748,000)	598,874
Change in fair value of warrant liability	(2,184,183)		(1,514,775)
Interest income	25,354	7,991	50,662	18,380
Interest expense	(9,708)	(50,894)	(37,063)	(59,020)
Net loss	(29,980,832)	(7,178,719)	(46,384,185)	(13,999,104)
Other comprehensive income (loss)	1,979,007	(345,019)	1,221,242	(475,914)
Comprehensive loss	(28,001,825)	(7,523,738)	(45,162,943)	(14,475,018)
Net loss	(29,980,832)	(7,178,719)	(46,384,185)	(13,999,104)
Accretion on convertible preferred C shares and warrants	(1,141,794)	(30,401)	(1,806,512)	(53,162)
Adjusted net loss	$ (31,122,626)	$ (7,209,120)	$ (48,190,697)	$ (14,052,266)
Basic and diluted net loss per ordinary share	$ (2.29)	$ (0.85)	$ (4.27)	$ (1.64)
Weighted-average number of ordinary shares outstanding	13,611,452	8,505,149	11,280,804	8,545,437

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) - 6 months ended Jun. 30, 2018 - USD ($)	Total	IPO [Member]	Convertible Preferred C Shares [Member]	Convertible Preferred C Shares [Member] Accounts Payable [Member]	Convertible Preferred C Shares [Member] License Agreement [Member]	Convertible Preferred C Shares [Member] Sales Agreement [Member]	A Ordinary Shares [Member]	A Ordinary Shares [Member] IPO [Member]	Capital in Excess of Nominal Value [Member]	Capital in Excess of Nominal Value [Member] IPO [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2017	$ (47,365,265)						$ 342		$ 20,080,713		$ (2,022,477)	$ (65,423,843)
Temporary equity, beginning Balance at Dec. 31, 2017			$ 51,338,631
Sale of A ordinary shares in initial public offering, net of issuance costs		$ 65,458,470						$ 194		$ 65,458,276
Beginning Balance, Shares at Dec. 31, 2017							8,826,190
Temporary equity, beginning Balance, Shares at Dec. 31, 2017	5,005,935		5,005,935
Accretion of issuance costs on convertible preferred C shares	$ (761,012)								(761,012)
Issuance of convertible preferred C shares, net of issuance costs				$ 1,356,129	$ 140,000	$ 56,159,119
Accretion of warrants issued in connection with convertible preferred C shares	(1,045,500)								(1,045,500)
Issuance of shares, net of issuance costs, Shares				129,419	13,360	5,425,124		5,000,000
Accretion of issuance costs on convertible preferred C shares			$ 761,012
Accretion of warrants issued in connection with convertible preferred C shares			1,045,500
Exercise of warrants	4,194,408		$ 9,720,000						4,194,408
Exercise of warrants, Share			927,594
Conversion convertible preferred C shares into A ordinary shares	120,520,391		$ (120,520,391)				$ 446		120,519,945
Conversion of convertible preferred C shares into A ordinary shares, Shares			(11,501,432)				11,501,432
Share-based compensation	$ 12,633,556						$ 73		12,633,483
Share-based compensation, Shares							1,856,510
Temporary equity, ending Balance, Shares at Jun. 30, 2018	0
Foreign currency translation	$ 1,221,242										1,221,242
Net loss	(46,384,185)											(46,384,185)
Ending Balance at Jun. 30, 2018	$ 108,472,105						$ 1,055		$ 221,080,313		$ (801,235)	$ (111,808,028)
Ending Balance, Shares at Jun. 30, 2018							27,184,132

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (29,980,832)	$ (7,178,719)	$ (46,384,185)	$ (13,999,104)
Adjustments to reconcile net loss to net cash used in operating activities:
Preferred C shares issued in connection with a license agreement			137,973
Share-based compensation expense			12,633,556	1,535,090
Foreign currency loss (gain)	2,726,624	(449,625)	1,748,000	(598,874)
Depreciation			1,015,079	373,276
Amortization of interest on asset retirement obligation			7,322	9,255	$ 19,313
Change in fair value of warrant liability	2,184,183		1,514,775
Decrease (increase) in operating assets:
Prepaid expenses and other current assets			317,130	6,134
Other current assets			650,528	(739,977)
Increase (decrease) in operating liabilities:
Deferred rent			(42,095)	784,493
Due to Kadmon			(861,030)	30,065
Accounts payable			(2,413,642)	1,646,167
Accrued expenses			(4,748,762)	352,544
Other liabilities				70,200
Net cash used in operating activities			(36,425,351)	(10,530,731)
Cash flows from investing activities:
Issuance of long-term note payable				2,500,000
Purchase of property and equipment			(1,318,016)	(4,824,514)
Net cash used in investing activities			(1,318,016)	(2,324,514)
Cash flows from financing activities:
Payments on capitalized lease obligation			(15,701)	(9,257)
Exercise of warrants			9,720,000
Proceeds from the sale of ordinary shares			69,750,000
Proceeds from the sale of convertible preferred C shares			56,849,592	210,244
Payment of note payable			(1,442,009)
Net cash provided by financing activities			131,469,856	194,863
Net increase (decrease) in cash, cash equivalents and restricted cash			93,726,489	(12,660,382)
Effect of exchange rate changes on cash			(214,576)	69,691
Cash, cash equivalents and restricted cash at beginning of period			8,672,014	17,921,485	17,921,485
Cash, cash equivalents and restricted cash at end of period	$ 102,183,927	$ 5,330,794	102,183,927	5,330,794	$ 8,672,014
Supplemental disclosure of non-cash transactions:
Fixed asset acquisition included in accounts payable and accrued expenses at end of period			298,551	1,561,299
Issuance of convertible preferred C shares in connection with payables			1,356,129
Conversion of convertible preferred C shares into ordinary shares			120,520,391
Reclassification of warrant liability upon exercise of warrants			4,194,408
Capitalized lease obligation for equipment purchase				78,063
Supplemental disclosure of cash flow information:
Cash paid for interest			31,531	1,337
A Ordinary Shares [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense			6,456,215
Cash flows from financing activities:
Issuance costs in connection with shares			(2,781,553)
Supplemental disclosure of non-cash transactions:
Issuance costs in connection with sale of convertible preferred C shares included in accrued expenses at end of period			1,509,977
Convertible Preferred C Shares [Member]
Cash flows from financing activities:
Issuance costs in connection with shares			(610,473)	$ (6,124)
Supplemental disclosure of non-cash transactions:
Issuance costs in connection with sale of convertible preferred C shares included in accrued expenses at end of period			$ 80,000

Summary of Significant Accounting Policies and Recent Accounting Pronouncements

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Recent Accounting Pronouncements

2.	Summary of Significant Accounting Policies and Recent Accounting Pronouncements:

Certain of the Company’s significant accounting policies are described below. All of the Company’s significant accounting policies are disclosed in the notes to the audited consolidated financial statements as of and for the year ended December 31, 2017 included in the Company’s Prospectus. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies.

Consolidation

The accompanying condensed consolidated financial statements include the accounts of Meira Holdings and its wholly owned subsidiaries:

MeiraGTx Limited, a limited company under the laws of England and Wales (“Meira Limited);

MeiraGTx, LLC, a Delaware corporation (“Meira LLC”);

BRI-Alzan, Inc., a Delaware corporation (“BRI-Alzan”);

MeiraGTx B.V., a Netherlands corporation (“Meira BV”);

MeiraGTx UK II Limited, (“Meira UK II”), a limited company under the laws of England and Wales;

MeiraGTx UK Limited (“Meira UK”), a limited company under the laws of England and Wales.

All intercompany balances and transactions between the consolidated companies have been eliminated in consolidation.

Use of Estimates

Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: valuation of A ordinary shares (“Ordinary Shares”) issued prior to the Company’s initial public offering, for the acquisition of assets, the accounting for research and development costs, warrants, share based compensation, asset retirement obligations and accrued expenses.

Fair Value Measurements

Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.

The Company follows ASC Topic 820, Fair Value Measurements and Disclosures, or ASC 820, for application to financial assets. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

•

Level 1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;

•

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

•

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The table below represents the values of the Compnay’s financial assets and liabilities that are required to be measured at fair value on a recurring basis:


	Fair Value Measurement Using:
Description	June 30, 2018		Significant Observable Inputs (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable (Level 3)
Restricted cash	$	123,376	$	123,376	$	—	$	—


	Fair Value Measurement Using:
Description	December 31, 2017		Significant Observable Inputs (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable (Level 3)
Restricted cash	$	123,376	$	123,376	$	—	$	—

Warrants	$	2,679,633	$	—	$	—	$	2,679,633

The table below represents a rollforward of the assets and liabilities that are required to be measured at fair value on a recurring basis from December 31, 2017 to June 30, 2018:


	Significant Unobservable Inputs (Level 3)
Balance as of December 31, 2017	$	2,679,633
Change in fair value of warrants		1,514,775
Exercise of warrants		(4,194,408	)

Balance as of June 30, 2018	$	—

The warrants were classified as liabilities because the underlying Preferred Shares had a redemption feature in the event of a change of control of the Company. On June 5, 2018, the warrants were exercised at which time the warrant liability was determined to be $4,194,408, which represented the difference in the market value of the Preferred Shares and the exercise price of the warrants. This resulted in an increase of the warrant liability in the amount of $2,184,183 and $1,514,775 for the three-month and six-month periods ended June 30, 2018, respectively. The related warrant liability of $4,194,408 was reclassified as Capital in Excess of Nominal Value at such time.

The fair values of the warrants at December 31, 2017, March 31, 2018 and June 4, 2018 were estimated using the Black-Scholes valuation model with the following assumptions:


	December 31, 2017			March 31, 2018			June 4, 2018
Risk-free interest rate		1.72	%		1.86	%		1.77	%
Expected volatility		80	%		80	%		80	%
Expected dividend yield		0			0			0
Expected life		9 months			5.5 months			1 day

For the unobservable inputs for the warrants, the expected volatility was determined at each measurement date by taking an average of the volatility of other publicly-traded peer biotechnology companies. The expected life was determined at each measurement date based upon the Company’s estimate of the time until the Company has a conversion event.

The fair value of the Preferred Shares was based upon recent issuances of the Company’s Preferred Shares on or about December 31, 2017, March 31, 2018 and June 5, 2018.

The estimated fair values of the Company’s warrants are not necessarily indicative of the amounts that would be realized in a current market exchange. The determination of the fair value of the warrants are sensitive to changes in in the assumptions used and a change in those inputs could result in a significantly higher or lower fair value measurement. If the volatility were to increase or the expected life were to increase, the fair value of the warrant would increase. Conversely, if the volatility were to decrease or the expected life were to decrease, the fair value of the warrant would decrease.

Net Loss per Ordinary Share

Basic net loss per Ordinary Share is computed by dividing net loss attributable to the Company’s shareholders by the weighted average number of shares of the Company’s Ordinary Shares assumed to be outstanding during the period of computation. Diluted net loss per ordinary share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional Ordinary Shares that would have been outstanding if the potential ordinary shares had been issued at the beginning of the year and if the additional ordinary shares were dilutive (treasury stock method) or the two-class method, whichever is more dilutive. For all periods presented, basic and diluted net loss per Ordinary Share are the same, as any additional Ordinary Share equivalents would be anti-dilutive.

Asset Retirement Obligation

Accounting for Asset Retirement Obligations requires legal obligations associated with the retirement of long-lived assets to be recognized at fair value when incurred and capitalized as part of the related long-lived asset. In the absence of quoted market prices, we estimate the fair value of our asset retirement obligations using Level 3 present value techniques, in which estimates of future cash flows associated with retirement activities are discounted using a credit-adjusted risk-free rate. Asset retirement obligations currently reported as other liabilities on our Consolidated Balance Sheet were measured during a period of historically low interest rates. The impact on measurements of new asset retirement obligations using different rates in the future may be significant.

The Company uses estimates to determine the amount of the asset retirement obligations at the end of the lease term and discounts such asset retirement obligations using an estimated discount rate. Interest on the discounted asset retirement obligation is amortized over the term of the lease using the effective interest method and is recorded as interest expense in the consolidated statements of operations and comprehensive loss.

The change in asset retirement obligations is as follows:


	For the six month period ended June 30, 2018			For the year ended December 31, 2017
Balance at beginning of period	$	178,419		$	221,254
Amortization of interest		7,322			19,313
Change in estimate		—			(75,011	)
Effects of exchange rate		(5,391	)		12,863

Balance at end of period	$	180,350		$	178,419

Research and Development

Research and development costs are charged to expense as incurred. These costs include, but are not limited to, employee-related expenses, including salaries, benefits and travel of the Company’s research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies and manufacture the drug product for the clinical studies and preclinical activities; acquisition of in-process research and development; facilities; supplies; rent, insurance, certain legal fees, stock-based compensation, depreciation and other costs associated with clinical and preclinical activities and regulatory operations. Refundable research and development tax credits received are recorded as an offset to these costs.

Costs for certain development activities, such as Company funded outside research programs, are recognized based on an evaluation of the progress to completion of specific tasks with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be.

Segment Information

Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations.

The following table summarizes non-current assets by geographical area:


	June 30, 2018		December 31, 2017
United States	$	413,481	$	436,463
United Kingdom		13,277,701		13,942,642

	$	13,691,182	$	14,379,105

Recent Accounting Pronouncements

In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Accounting, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU 2018-07generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business, or ASU 2017-01, that clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 requires an entity to evaluate if substantially all of the fair value of the gross assets acquired or disposed of is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities is not a business. ASU 2017-01 also requires a business to include at least an input and one substantive process that together significantly contribute to the ability to create output and removes the evaluation of whether a market participant could replace missing elements. ASU 2017-01 should be applied prospectively and is effective for annual periods beginning after December 15, 2017 and interim periods within those annual periods. The adoption of ASU 2017-01 on January 1, 2018 did not have a material effect on the Company’s financial position, results of operations or cash flows.

In December 2016, the FASB issued ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, or ASU 2016-20, that allows entities not to disclose variable consideration allocated to performance obligations related to either: (1) sales—or usage -based royalties on licenses of intellectual property or (2) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation when certain criteria are met. ASU 2016-20 also requires entities that use any of the new or previously existing optional exemptions to expand their qualitative disclosures. It also makes 12 additional technical corrections and improvements to the new revenue standard, ASU 2014-09. The amendments have the same effective date and transition requirements as ASU 2014-09. The adoption of ASU 2016-20 did not have a material effect on its financial position, results of operations or cash flows.

In November 2016, the Financial Accounting Standards Board, or FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash (a consensus of the Emerging Issues Task Force), orASU 2016-18, which changes the presentation of the cash flow statement to include amounts generally described as restricted cash or restricted cash equivalents, together with cash and cash equivalents, when reconcilingthe beginning-of-period and end-of-period amounts shown on the statement of cash flows. ASU 2016-18 also requires additional disclosures concerning the nature of the restrictions on cash and cash equivalents and a reconciliation between amounts of cash, cash equivalents and restricted cash on the balance sheet and statement of cash flows for each period presented. ASU 2016-18 will be applied retrospectively to all periods presented and is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. Prior to adoption, the Company presented changes in restricted cash as an operating activity in the statement of cash flows. Upon adoption of ASU 2016-18 on January 1, 2018, such changes are now reflected in the beginning and ending balances of cash, cash equivalents and restricted cash for all periods presented.

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory, or ASU 2016-16 which requires that an entity recognize the income tax consequences of an intra-entity transfer of assets other than inventory when the transfer occurs. The guidance must be applied using the modified retrospective basis. The Company does not expect the provisions of ASU 2016-16 to have a material impact on its current financial statements. This update will be effective for the Company at the beginning of fiscal 2019.

In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients, or ASU 2016-12, which amends guidance in the new revenue standard, ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), or ASU 2014-09, on collectability, noncash consideration, presentation of sales tax and transition. The amendments in ASU 2016-12 areeffective for annual reporting periods beginning after December 15, 2017 (i.e., January 1, 2018), including interim periods within those reporting periods, which is the same as for ASU 2014-09, as amended by ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, or ASU 2015-14. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, or ASU 2016-10, which clarifies the principle for determining whether a good or service is “separately identifiable” from other promises in the contract and, therefore, should be accounted for as a separate performance obligation. In that regard, ASU 2016-10 requires that an entity determine whether its promise is to transfer individual goods or services to the customer, or a combined item (or items) to which the individual goods and services are inputs. In addition, ASU 2016-10 categorizes intellectual property, or IP, into two categories: “functional” and “symbolic.” Functional IP has significant standalone functionality. All other IP is considered symbolic IP. Revenue from licenses of functional IP is generally recognized at a point in time, while revenue from licenses of symbolic IP is recognized over time. ASU 2016-10 has the same effective date and transition requirements as ASU 2014-09, as amended by ASU 2015-14. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net), or ASU 2016-08, which clarifies the implementation guidance on principal versus agent considerations contained in ASU 2014-09 by specifying that the determination as to whether an entity that is involved in providing a good or a service to a customer is a principal or an agent is based upon whether the entity controls the good or the service before it is transferred to the customer. ASU 2016-08 has the same effective date and transition requirements as ASU 2014-09, as amended by ASU 2015-14. The adoption of these ASU’s on January 1, 2018 did not have a material effect on the Company’s financial position, results of operations or cash flows.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, or ASU 2014-09, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of ASU 2014-09 is that an entity should recognize revenue when it transfers control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 for public companies and December 15, 2018 for non-public companies. The Company is allowed to adopt ASU 2014-09 either (1) retrospectively to each prior reporting period presented using several practical expedients related to completed contracts and required disclosures, or (2) using a modified retrospective approach, with the cumulative effect of initially applying ASU 2014-09 recognized as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application, including disclosure of the effect of using this method of adoption on the financial statement line items. Because the Company has no contracts with customers, the adoption of ASU 2014-09 on January 1, 2018 did not have a material effect on the Company’s financial position, results of operations or cash flows.

Share-Based Compensation

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

4.	Share-Based Compensation

2018 and 2016 Equity Incentive Plans

The Company maintains the 2018 Incentive Award Plan and 2016 Equity Incentive Plan (together, the “Plans”), under which, the Company has granted share options to selected officers, employees and non-employeeconsultants. The Company’s board of directors administer the Plans. Options granted under the Plans have a maximum contractual term of ten years. Options granted to employees and consultants generally vest 25% on the first anniversary date of grant and the balance ratably over the next 36 months. Options granted to directors generally vest on the first anniversary date of grant. Upon the adoption of the 2018 Incentive Award Plan, the Company ceased issuing awards under the 2016 Equity Incentive Plan.

A summary of the Company’s share option activity related to employees, non-employee members of the board of directors and non-employee consultants as of and for the six-month period ended June 30, 2018 is as follows:


	Number of Options		Weighted- Average Exercise Price		Aggregate Instrinsic Value
Outstanding at December 31, 2017		938,637	$	5.12	$	1,420,650
Granted		675,685		5.63
Exercised		—		—
Expired		—		—
Forfeited		—		—

Outstanding at June 30, 2018		1,614,322	$	5.34	$	9,884,932

Weighted average remaining contractual life of options outstanding as of December 31, 2017 (yrs)		9.09

Weighted average remaining contractual life of options outstanding as of June 30, 2018 (yrs)		8.97

Options exercisable at December 31, 2017		186,395	$	7.72	$	—

Options exercisable at June 30, 2018		265,221	$	7.69	$	999,410

Weighted average remaining contractual life of options exercisable as of December 31, 2017 (yrs)		8.21

Weighted average remaining contractual life of options exercisable as of June 30, 2018 (yrs)		7.86

The total fair value of options vested during the three-month periods ended June 30, 2018 and 2017 was $247,202 and $229,250, respectively.

The total fair value of options vested during the six-month periods ended June 30, 2018 and 2017 was $556,349 and $927,915, respectively.

During the six-month periods ended June 30, 2018 and 2017, the Company granted 533,330 and 0 share options, respectively, to employees and non-employee members of the board of directors. No options were granted during the three-month periods ended June 30, 2018 and 2017. The grant date fair values of the stock options granted to those groups were estimated using the Black-Scholes option valuation model with the following ranges of assumptions:


		2018
Risk-free interest rate		2.32% - 2.40%
Expected volatility		90%
Expected dividend yield		0%
Expected life of employee and Board of Directors’ options (in years)		5.5 - 6.1

As of June 30, 2018, the total compensation expense relating to unvested options granted to employees and non-employee members of the board of directors that had not yet been recognized was $2,596,655, which is expected to be realized over a period of 3.5 years. The Company will issue shares upon exercise of options from Ordinary Shares reserved.

During the six-month periods ended June 30, 2018 and 2017, the Company granted 142,355 and 135,271 share options, respectively to non-employee consultants. No options were granted during the three-month period ended June 30, 2018. In accordance with ASC 505-50, on June 30, 2017 and 2018, the Company remeasured the fair value, of all unvested outstanding options that had been granted to non-employee consultants using the Black-Scholes option valuation model with the following ranges of assumptions:


	2018	2017
Risk-free interest rate	2.80% - 2.84%	2.29% - 2.31%
Expected volatility	90%	80%
Expected dividend yield	0%	0%
Expected life of non-employee options (in years)	7.7 - 9.5	8.7 - 9.7

As of June 30, 2018, the total compensation expense relating to unvested options granted to non-employee consultants that had not yet been recognized was $3,823,995, which is expected to be realized over a period of 3.5 years. The Company will issue shares upon exercise of options from Ordinary Shares reserved.

The weighted average grant date fair value of options granted to employees, non-employee members of the board of directors and non-employee consultants during the six-month periods ended June 30, 2018 and 2017 was $5.63 and $6.13, respectively.

Restricted Ordinary Shares

In 2015, in connection with certain service and consulting agreements, certain employees and a consultant were awarded an aggregate of 867,935 restricted Ordinary Shares of the Company. Such shares were subject to forfeiture over a three-year service period. The shares granted to the consultant and employees were valued at $7.72 and $7.76 per share, respectively, and were included in loss from operations over the requisite service period. As of June 30, 2018, all such shares are no longer subject to forfeiture as the three-year service period has been completed.

On June 7, 2018, 1,306,348 restricted Ordinary Shares, which represented 5% of the fully-diluted outstanding shares of the Company as of such date, were issued to certain members of senior management in accordance with their employment agreements. One-third of such shares vested immediately, with the balance vesting quarterly over the next eight quarters beginning three months after the effectiveness of the Company’s registration statement on Form S-1 filed with the SEC on June 7, 2018 (the “Registration Statement”). The shares were valued at $15.00 per share and are included in loss from operations over the requisite service period. Additionally, under the terms of the employment agreements, the Company was required to pay the income taxes incurred by the grantees in connection with the grant of those restricted shares. Total compensation expense in connection with the issuance of those restricted Ordinary Shares, in the amount of $13,620,866, of which $6,531,750 was share-based, was recorded as general and administrative expense during the three-month period ended June 30, 2018.

A summary of the restricted Ordinary Shares is as follows:


	Ordinary Shares			$ Value
Non-vested at December 31, 2017		105,913		$	865,861
Issued during the six-month period ended June 30, 2018		1,306,348			19,595,220
Vesting during the six-month period ended June 30, 2018		(541,363	)		(7,397,611	)

Non-vested at June 30, 2018		870,898		$	13,063,470

Ordinary Shares

On March 1, 2018, a funding milestone was met under the employment agreements for certain members of senior management. Accordingly, the employees were issued an aggregate of 550,162 fully vested Ordinary Shares, which represented 3% of the fully-diluted outstanding shares of the Company as of such date. The shares were recorded as share-based compensation in the amount of $3,096,104. Additionally, under the terms of the employment agreements, the Company was required to pay the income taxes incurred by the grantees in connection with the grant of those shares. Total compensation expense in connection with the issuance of those Ordinary Shares, in the amount of $6,456,215, of which $3,096,012 was share-based, was recorded as general and administrative expense during the six-month period ended June 30, 2018.

During the three-month and six-month periods ended June 30, 2018 and 2017 the Company recognized total share-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss as follows:


	Three-month periods ended June 30,
	2018		2017
Research and development	$	1,045,561	$	550,708
General and administrative		7,318,224		131,427

Total share based compensation	$	8,363,785	$	682,135


	Six-month periods ended June 30,
	2018		2017
Research and development	$	1,890,511	$	1,239,923
General and administrative		10,743,045		295,167

Total share based compensation	$	12,633,556	$	1,535,090

The Company does not expect to realize any tax benefits from its share option activity or the recognition of share-based compensation expense because the Company currently has net operating losses and has a full valuation allowance against its deferred tax assets. Accordingly, no amounts related to excess tax benefits have been reported in cash flows from operations or cash flows from financing activities for the three-month and six-monthperiods ended June 30, 2018 and 2017.

Related Party Transactions

6 Months Ended

Jun. 30, 2018

Related Party Transactions

8.	Related Party Transactions:

Transition Services Agreement

Effective April 24, 2015, the Company entered into a three-year transition services agreement (the “TSA”) with Kadmon, whereby Kadmon would provide office and laboratory facilities as well as certain other personnel support activities to the Company. Under the agreement, the Company was charged for (i) rent based upon the square footage of the office and laboratory facilities used by the Company (ii) other personnel support activities based upon the hours of the personnel providing the support activities, and (iii) and other direct costs incurred by Kadmon on behalf of the Company, plus a 7% administrative fee. The TSA terminated on April 24, 2018 and the Company is currently leasing office space on a month to month basis from Kadmon.

During the three-month periods ended June 30, 2018 and 2017, the Company incurred the following charges from Kadmon, which are included in loss from operations:


	2018		2017
Rent	$	139,321	$	152,169
Personnel		—		6,746
Other		—		126

Total charges incurred	$	139,321	$	159,041

During the six-month periods ended June 30, 2018 and 2017, the Company incurred the following charges from Kadmon, which are included in loss from operations:


	2018		2017
Rent	$	275,674	$	275,524
Personnel		6,493		25,278
Other		—		5,206

Total charges incurred	$	282,167	$	306,008

During the three-month periods ended June 30, 2018 and 2017, the Company made cash payments totaling $145,887 and $0, respectively, to Kadmon.

During the six-month periods ended June 30, 2018 and 2017, the Company made cash payments totaling $1,143,304 and $275,941, respectively, to Kadmon.

The amount due to Kadmon at June 30, 2018 and December 31, 2017 is $0 and $861,030, respectively and is disclosed as Due to Kadmon on the Company’s condensed consolidated balance sheets.

Research Agreement

Effective October 23, 2016, the Company entered into a four-year master services agreement with UCL Consultants Limited, an entity affiliated with University College of London (“UCL”), which is a shareholder of the Company. Pursuant to the agreement, UCL Consultants Limited provides pre-clinical research and development under the direction of the Company. In connection with the agreement, the Company issued several work orders during the years ended December 31, 2016 and 2017 in the aggregate amounts of £1,161,149 and £241,053, respectively, or approximately $1,574,000 and $311,000, based upon the average exchange rates during the years ended December 31, 2016 and 2017, respectively. Either party may terminate the agreement by giving 30 days written notice.

Total research and development expenses under this agreement for the three-month periods ended June 30, 2018 and 2017 were approximately $183,000 and $114,000, respectively.

Total research and development expenses under this agreement for the six-month periods ended June 30, 2018 and 2017 was approximately $372,000 and $222,000, respectively.

Future obligations, under the agreement equal £797,343, or approximately $1,052,791 through October 2020.

The amount due to UCL under the master services agreement at June 30, 2018 and December 31, 2017 is $374,873 and $775,315, respectively, and is included in accounts payable and accrued expenses on the condensed consolidated balance sheets.

Manufacturing Agreement

Effective September 1, 2016, the Company entered into a manufacturing and drug supply agreement with UCL. Pursuant to the agreement, UCL manufactured materials for the Company’s clinical trials under the direction of the Company. Either party could terminate the agreement by giving 30 days written notice. The agreement was terminated in January 2018.

Total research and development expenses under this agreement for the three-month periods ended June 30, 2018 and 2017 was approximately $0 and $479,494, respectively.

Total research and development expenses under this agreement for the six-month periods ended June 30, 2018 and 2017 was approximately $0 and $1,042,518, respectively.

The amount due to UCL under the manufacturing and drug supply agreement at June 30, 2018 and December 31, 2017 is $374,983 and $2,466,142, respectively, and is included in accrued expenses in the condensed consolidated balance sheet.

License Agreement

Effective March 15, 2018, the Company entered into an exclusive worldwide license agreement with UCL Business, PLC (“UCL Business”), to develop up to eight programs using certain ocular gene therapy technology. Under the terms of the agreement, the Company has agreed to pay UCL Business certain sales milestone payments, if achieved, in the aggregate amount of £39.8 million, or approximately $52.6 million using the exchange rate at June 30, 2018, and royalties on net sales, as defined upon commercialization. Additionally, the Company is responsible for all patent prosecution and maintenance costs incurred and has also agreed to pay UCL Business an annual maintenance fee of £50,000, or approximately $66,000, until the first commercial sale of a product. The agreement will terminate upon the later of (i) the last valid claim in a relevant product (ii) the expiration of regulatory exclusivity to all licensed products, or (iii) the 10^th anniversary of the first commercial sale of a product.

The Company did not incur any research and development expenses under the agreement during the three-month and six-month periods ended June 30, 2018 and 2017.

Leases

December 2016 Lease

Effective December 15, 2016, the Company entered into another non-cancellable operating lease with ARE, expiring on October 31, 2032, for laboratory and office facilities in New York. The lease provided for monthly base rent, including rent escalations, property management fees and rent holidays, plus operating expenses during the lease term. The Company recorded monthly rent expense on a straight-line basis from December 15, 2016 through October 31, 2032. On October 26, 2017, the lease was amended, whereby the lease would terminate on March 31, 2018 and only base rent and management fees in the aggregate amount of $563,507 would be due from November 1, 2017 through March 31, 2018. Under the amendment, the Company issued a note to ARE in the amount of $1,442,009, removed the balance of the deferred rent and accrued the future rent payments, all of which were recorded as rent expense at the time of the amendment, in accordance with ASC 420, Exit and Disposal Activities, as the Company had a cease use date as of the date of the amendment. Tthe balance of deferred lease obligation, representing the difference between cash rent paid and straight-line rent expense, was $0 as of December 31, 2017 and June 30, 2018,.

Total rent expense under this operating lease was $0 and $390,903 for the three-month periods ended June 30, 2018 and 2017, respectively.

Total rent expense under this operating lease was $0 and $781,806 for the six-month periods ended June 30, 2018 and 2017, respectively.

On October 26, 2017, in connection with the amendment to the lease, the Company issued a promissory note in the amount of $1,442,009 to ARE. The note accrued interest at the rate of 5% per annum and was due on December 31, 2018. However, if the Company had sufficient liquidity, as defined in the note, then the note, including accrued interest, would become due and payable at that time. In accordance with the sufficient liquidity provision, the Company repaid the note, plus accrued interest, in the aggregate amount of $1,472,433 during the three-month period ended March 31, 2018.

The Company recorded interest expense of $0 and $30,424 for the three-month and six-month periods ended June 30, 2018.

July 2016 Lease

Effective July 1, 2016, the Company entered into a non-cancellable operating lease for laboratory and related office facilities in New York with ARE, an entity that is under common control by an entity that is a minority shareholder of the Company and whose CEO is a director of the Company. The lease provides for monthly base rent and property management fees, including rent escalations and rent holidays, plus operating expenses during the lease term, which expires on December 31, 2021. The Company records monthly rent expense on a straight-line basis from July 1, 2016 through December 31, 2021. As of June 30, 2018 and December 31, 2017, the balance of deferred rent, representing the difference between cash rent paid and straight-line rent expense, was $220,722 and $231,276, respectively.

Total rent expense under this operating lease was $121,890 and $121,890 for the three-month periods ended June 30, 2018 and 2017, respectively.

Total rent expense under this operating lease was $243,780 and $243,780 for the six-month periods ended June 30, 2018 and 2017, respectively.

As of June 30, 2018, the aggregate future minimum rental payments under this lease are $1,927,187.

In connection with the signing of this lease, the Company entered into a standby letter of credit agreement for $122,866, which serves as a security deposit for the premises. The standby letter of credit expires on July 7, 2017 and is automatically renewed annually through July 7, 2021. This standby letter of credit is secured with restricted cash in a money market account.

Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

The Company

The Company

MeiraGTx Holdings plc, a limited company under the laws of the Cayman Islands, is a clinical-stage biotech company developing novel gene therapy treatments for a wide range of inherited and acquired disorders for which there are no effective treatments available. The Company is focused on developing therapies for ocular diseases, including rare inherited blindness as well as Xerostomia following radiation treatment for head and neck cancers and neurodegenerative diseases such as amyothrophic lateral sclerosis (“ALS”).

Risks and Uncertainties

Risks and Uncertainties

The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.

The Company’s limited capital resources and operations to date have been funded primarily with the proceeds from private equity offerings and the IPO. In the future, the Company may seek to raise additional capital through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable it to complete the development and potential commercialization of its product candidates.

Basis of Presentation

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Reverse Share Split

Reverse Share Split

On June 7, 2018 MeiraGTx Limited’s Board of Directors and shareholders approved a 1:3.881 reverse share split. All share information presented in these financial statements and accompanying footnotes have been retroactively adjusted to reflect the decreased number of shares resulting from this action.

Liquidity

Liquidity

The Company has not generated any revenues and has not yet achieved profitable operations. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis. In addition, development activities, clinical and preclinical testing, and commercialization of the Company’s product candidates will require significant additional financing. Management expects to incur substantial and increasing losses in future periods. The success of the Company is subject to certain risks and uncertainties, including among others, uncertainty of product development; competition in the Company’s field of use; uncertainty of capital availability; uncertainty in the Company’s ability to enter into agreements with collaborative partners; dependence on third parties; and dependence on key personnel. The Company has not generated positive cash flows from operations, and there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.

As of June 30, 2018, the Company had cash and cash equivalents in the amount of $102,060,551, which consisted of depository accounts. The Company estimates that its cash and cash equivalents on hand at June 30, 2018 will cover its expenses into the second quarter of 2020.

Reorganization and Initial Public Offering

Reorganization and Initial Public Offering

On May 28, 2018, the Board of Directors of MeiraGTx Limited approved the Reorganization Transactions, effective June 7, 2018, pursuant to which the Board of Directors approved the transfer of the shares held by each of the MeiraGTx Limited’s shareholders for the equivalent class and number of shares issued by Meira Holdings. On June 7, 2018, the Company completed its IPO, selling 5,000,000 Series A ordinary shares (“Ordinary Shares”) at a public offering price of $15.00 per share, and receiving $65.9 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses payable by us.

Interim Financial Statements

Interim Financial Statements

The accompanying condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments (consisting of normal recurring accruals) necessary in order to make the condensed consolidated financial statements not misleading. Operating results for the three-month and six-month periods ended June 30, 2018 are not necessarily indicative of the final results that may be expected for the year ended December 31, 2018. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2017 and the notes thereto for the year ended December 31, 2017 included in the Company’s final prospectus that forms a part of the Company’s Registration Statement on Form S-1 (Reg. No. 333-224914), filed with the Securities and Exchange Commission (“SEC”) pursuant to Rule 424(b)(4) on June 8, 2018 (the “Prospectus”).

Consolidation

Consolidation

The accompanying condensed consolidated financial statements include the accounts of Meira Holdings and its wholly owned subsidiaries:

MeiraGTx Limited, a limited company under the laws of England and Wales (“Meira Limited);

MeiraGTx, LLC, a Delaware corporation (“Meira LLC”);

BRI-Alzan, Inc., a Delaware corporation (“BRI-Alzan”);

MeiraGTx B.V., a Netherlands corporation (“Meira BV”);

MeiraGTx UK II Limited, (“Meira UK II”), a limited company under the laws of England and Wales;

MeiraGTx UK Limited (“Meira UK”), a limited company under the laws of England and Wales.

All intercompany balances and transactions between the consolidated companies have been eliminated in consolidation.

Use of Estimates

Use of Estimates

Fair Value Measurements

Fair Value Measurements

•

Level 1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;

•

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

•

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The table below represents the values of the Compnay’s financial assets and liabilities that are required to be measured at fair value on a recurring basis:


	Fair Value Measurement Using:
Description	June 30, 2018		Significant Observable Inputs (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable (Level 3)
Restricted cash	$	123,376	$	123,376	$	—	$	—


	Fair Value Measurement Using:
Description	December 31, 2017		Significant Observable Inputs (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable (Level 3)
Restricted cash	$	123,376	$	123,376	$	—	$	—

Warrants	$	2,679,633	$	—	$	—	$	2,679,633

The table below represents a rollforward of the assets and liabilities that are required to be measured at fair value on a recurring basis from December 31, 2017 to June 30, 2018:


	Significant Unobservable Inputs (Level 3)
Balance as of December 31, 2017	$	2,679,633
Change in fair value of warrants		1,514,775
Exercise of warrants		(4,194,408	)

Balance as of June 30, 2018	$	—

The fair values of the warrants at December 31, 2017, March 31, 2018 and June 4, 2018 were estimated using the Black-Scholes valuation model with the following assumptions:


	December 31, 2017			March 31, 2018			June 4, 2018
Risk-free interest rate		1.72	%		1.86	%		1.77	%
Expected volatility		80	%		80	%		80	%
Expected dividend yield		0			0			0
Expected life		9 months			5.5 months			1 day

The fair value of the Preferred Shares was based upon recent issuances of the Company’s Preferred Shares on or about December 31, 2017, March 31, 2018 and June 5, 2018.

Net Loss per Ordinary Share

Net Loss per Ordinary Share

Asset Retirement Obligation

Asset Retirement Obligation

The change in asset retirement obligations is as follows:


	For the six month period ended June 30, 2018			For the year ended December 31, 2017
Balance at beginning of period	$	178,419		$	221,254
Amortization of interest		7,322			19,313
Change in estimate		—			(75,011	)
Effects of exchange rate		(5,391	)		12,863

Balance at end of period	$	180,350		$	178,419

Research and Development

Research and Development

Segment Information

Segment Information

Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations.

The following table summarizes non-current assets by geographical area:


	June 30, 2018		December 31, 2017
United States	$	413,481	$	436,463
United Kingdom		13,277,701		13,942,642

	$	13,691,182	$	14,379,105

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Accounting, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.

In November 2016, the Financial Accounting Standards Board, or FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash (a consensus of the Emerging Issues Task Force), or ASU 2016-18, which changes the presentation of the cash flow statement to include amounts generally described as restricted cash or restricted cash equivalents, together with cash and cash equivalents, when reconciling the beginning-of-period and end-of-period amounts shown on the statement of cash flows. ASU 2016-18 also requires additional disclosures concerning the nature of the restrictions on cash and cash equivalents and a reconciliation between amounts of cash, cash equivalents and restricted cash on the balance sheet and statement of cash flows for each period presented. ASU 2016-18 will be applied retrospectively to all periods presented and is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. Prior to adoption, the Company presented changes in restricted cash as an operating activity in the statement of cash flows. Upon adoption of ASU 2016-18 on January 1, 2018, such changes are now reflected in the beginning and ending balances of cash, cash equivalents and restricted cash for all periods presented.

In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients, or ASU 2016-12, which amends guidance in the new revenue standard, ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), or ASU 2014-09, on collectability, noncash consideration, presentation of sales tax and transition. The amendments in ASU 2016-12 are effective for annual reporting periods beginning after December 15, 2017 (i.e., January 1, 2018), including interim periods within those reporting periods, which is the same as for ASU 2014-09, as amended by ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, or ASU 2015-14. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, or ASU 2016-10, which clarifies the principle for determining whether a good or service is “separately identifiable” from other promises in the contract and, therefore, should be accounted for as a separate performance obligation. In that regard, ASU 2016-10 requires that an entity determine whether its promise is to transfer individual goods or services to the customer, or a combined item (or items) to which the individual goods and services are inputs. In addition, ASU 2016-10 categorizes intellectual property, or IP, into two categories: “functional” and “symbolic.” Functional IP has significant standalone functionality. All other IP is considered symbolic IP. Revenue from licenses of functional IP is generally recognized at a point in time, while revenue from licenses of symbolic IP is recognized over time. ASU 2016-10 has the same effective date and transition requirements as ASU 2014-09, as amended by ASU 2015-14. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net), or ASU 2016-08, which clarifies the implementation guidance on principal versus agent considerations contained in ASU 2014-09 by specifying that the determination as to whether an entity that is involved in providing a good or a service to a customer is a principal or an agent is based upon whether the entity controls the good or the service before it is transferred to the customer. ASU 2016-08 has the same effective date and transition requirements as ASU 2014-09, as amended by ASU 2015-14. The adoption of these ASU’s on January 1, 2018 did not have a material effect on the Company’s financial position, results of operations or cash flows.

Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Compnay's Financial Assets and Liabilities Measured at Fair Value

The table below represents the values of the Compnay’s financial assets and liabilities that are required to be measured at fair value on a recurring basis:


	Fair Value Measurement Using:
Description	June 30, 2018		Significant Observable Inputs (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable (Level 3)
Restricted cash	$	123,376	$	123,376	$	—	$	—


	Fair Value Measurement Using:
Description	December 31, 2017		Significant Observable Inputs (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable (Level 3)
Restricted cash	$	123,376	$	123,376	$	—	$	—

Warrants	$	2,679,633	$	—	$	—	$	2,679,633

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

The table below represents a rollforward of the assets and liabilities that are required to be measured at fair value on a recurring basis from December 31, 2017 to June 30, 2018:


	Significant Unobservable Inputs (Level 3)
Balance as of December 31, 2017	$	2,679,633
Change in fair value of warrants		1,514,775
Exercise of warrants		(4,194,408	)

Balance as of June 30, 2018	$	—

Fair Values of Warrants Estimated by Using Black-Scholes Valuation Model

The fair values of the warrants at December 31, 2017, March 31, 2018 and June 4, 2018 were estimated using the Black-Scholes valuation model with the following assumptions:


	December 31, 2017			March 31, 2018			June 4, 2018
Risk-free interest rate		1.72	%		1.86	%		1.77	%
Expected volatility		80	%		80	%		80	%
Expected dividend yield		0			0			0
Expected life		9 months			5.5 months			1 day

Schedule of change in asset retirement obligations

The change in asset retirement obligations is as follows:


	For the six month period ended June 30, 2018			For the year ended December 31, 2017
Balance at beginning of period	$	178,419		$	221,254
Amortization of interest		7,322			19,313
Change in estimate		—			(75,011	)
Effects of exchange rate		(5,391	)		12,863

Balance at end of period	$	180,350		$	178,419

Summary of Non-Current Assets by Geographical Area

The following table summarizes non-current assets by geographical area:


	June 30, 2018		December 31, 2017
United States		413,481		436,463
United Kingdom		13,277,701		13,942,642

		13,691,182		14,379,105

Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Company's Share Option Activity Related to Employees, Non-Employee Members of the Board of Directors and Non-Employee Consultants


	Number of Options		Weighted- Average Exercise Price		Aggregate Instrinsic Value
Outstanding at December 31, 2017		938,637	$	5.12	$	1,420,650
Granted		675,685		5.63
Exercised		—		—
Expired		—		—
Forfeited		—		—

Outstanding at June 30, 2018		1,614,322	$	5.34	$	9,884,932
Weighted average remaining contractual life of options outstanding as of December 31, 2017 (yrs)		9.09

Weighted average remaining contractual life of options outstanding as of June 30, 2018 (yrs)		8.97

Options exercisable at December 31, 2017		186,395	$	7.72	$	—

Options exercisable at June 30, 2018		265,221	$	7.69	$	999,410

Weighted average remaining contractual life of options exercisable as of December 31, 2017 (yrs)		8.21

Weighted average remaining contractual life of options exercisable as of June 30, 2018 (yrs)		7.86

Schedule of Grant Date Fair Values of the Stock Option Granted

The grant date fair values of the stock options granted to those groups were estimated using the Black-Scholes option valuation model with the following ranges of assumptions:


		2018
Risk-free interest rate		2.32% - 2.40%
Expected volatility		90%
Expected dividend yield		0%
Expected life of employee and Board of Directors’ options (in years)		5.5 - 6.1


	2018	2017
Risk-free interest rate	2.80% - 2.84%	2.29% - 2.31%
Expected volatility	90%	80%
Expected dividend yield	0%	0%
Expected life of non-employee options (in years)	7.7 - 9.5	8.7 - 9.7

Summary of Restricted Ordinary Shares

A summary of the restricted Ordinary Shares is as follows:


	Ordinary Shares			$ Value
Non-vested at December 31, 2017		105,913		$	865,861
Issued during the six-month period ended June 30, 2018		1,306,348			19,595,220
Vesting during the six-month period ended June 30, 2018		(541,363	)		(7,397,611	)

Non-vested at June 30, 2018		870,898		$	13,063,470

Schedule of Share Based Compensation Expense


	Three-month periods ended June 30,
	2018		2017
Research and development	$	1,045,561	$	550,708
General and administrative		7,318,224		131,427

Total share based compensation	$	8,363,785	$	682,135


	Six-month periods ended June 30,
	2018		2017
Research and development	$	1,890,511	$	1,239,923
General and administrative		10,743,045		295,167

Total share based compensation	$	12,633,556	$	1,535,090

Share based Compensation - Additional Information (Detail) - USD ($)			3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 07, 2018	Mar. 01, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual life of options outstanding					8 years 11 months 19 days		9 years 1 month 2 days
Fair value of options Vested			$ 247,202	$ 229,250	$ 556,349	$ 927,915
Share options granted during the period					675,685
Fully-diluted outstanding shares	5.00%
Share based compensation					$ 12,633,556	1,535,090
Excess Tax Benefit from Share-based Compensation, Operating Activities			0	0	0	0
Excess Tax Benefit from Share-based Compensation, Financing Activities			0	$ 0	$ 0	$ 0
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual life of options outstanding					10 years
A Ordinary Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares awarded, per share	$ 15.00
Fully-diluted outstanding shares		3.00%
Share based compensation		$ 3,096,104			$ 6,456,215
Ordinary shares, issued	5,000,000	550,162
A Ordinary Shares [Member] \| General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation					$ 3,096,012
Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares	1,306,348				1,306,348
Ordinary shares forfeiture period								3 years
Ordinary shares awarded, per share	$ 15.00
Fully-diluted outstanding shares	5.00%
Share based compensation			13,620,866
Restricted Shares [Member] \| General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation			$ 6,531,750
Restricted Shares [Member] \| A Ordinary Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares								867,935
Employee and Non Employee Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share options granted during the period			0	0	533,330	0
Total unvested options compensation expense			$ 2,596,655		$ 2,596,655
Unvested options expected to be realized					3 years 6 months
Weighted average grant date fair value of options granted					$ 5.63	$ 6.13
Non-employee consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share options granted during the period			0		142,355	135,271
Total unvested options compensation expense			$ 3,823,995		$ 3,823,995
Unvested options expected to be realized					3 years 6 months
Consultant [Member] \| Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares awarded, per share			$ 7.72		$ 7.72
Employee [Member] \| Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares awarded, per share			$ 7.76		$ 7.76
First Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage					25.00%
Over Three Years [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					36 months

Share Based Compensation - Summary of Company's Share Option Activity Related to Employees, Non-Employee Members of the Board of Directors and Non-Employee Consultants (Detail) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of options, Beginning balance		938,637
Number of options, Granted		675,685
Number of options, Exercised		0
Number of options, Expired		0
Number of options, Forfeited		0
Number of options, Ending balance	1,614,322	1,614,322	938,637
Weighted average remaining contractual life of options outstanding		8 years 11 months 19 days	9 years 1 month 2 days
Number of options, Options exercisable	265,221		186,395
Weighted average remaining contractual life of options exercisable		7 years 10 months 9 days	8 years 2 months 15 days
Weighted- average exercise price, beginning balance		$ 5.12
Weighted- average exercise price, granted		5.63
Weighted- average exercise price, exercised		0
Weighted- average exercise price, expired		0
Weighted- average exercise price, forfeited		0
Weighted- average exercise price, ending balance	$ 5.34	$ 5.12	$ 5.12
Weighted- average exercise price, option exercisable	$ 7.69		$ 7.72
Aggregate Intrinsic Value, Beginning balance		$ 1,420,650
Aggregate Intrinsic Value, Ending balance	$ 9,884,932	$ 9,884,932	$ 1,420,650
Aggregate Intrinsic Value, Options exercisable	$ 999,410

Ordinary Shares and Convertible Preferred C Shares - Additional Information (Detail) - USD ($)					3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 07, 2018	Jun. 05, 2018	Mar. 15, 2018	Mar. 01, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2015
Percentage of fully diluted shares	5.00%
Preferred shares, purchase		927,594
Preferred shares, exercise price		$ 10.48
Preferred shares, value		$ 9,720,000					$ 9,720,000
Gross proceeds from preferred shares							56,849,592	$ 210,244
Preferred share conversion value	$ 664,718				$ 666,567	$ 30,401	$ 761,012	53,162
Restricted Shares [Member]
Ordinary shares, offering price	$ 15.00
Ordinary shares	1,306,348						1,306,348
Percentage of fully diluted shares	5.00%
A Ordinary Shares [Member]
Ordinary shares, issued	5,000,000			550,162
Ordinary shares, offering price	$ 15.00
Proceeds from issuance initial public offering	$ 75,000,000
Offering costs	$ 9,541,530						$ 2,781,553
Percentage of fully diluted shares				3.00%
Preferred shares conversion into ordinary shares	11,501,432						11,501,432
A Ordinary Shares [Member] \| Restricted Shares [Member]
Ordinary shares									867,935
Preferred C Shares [Member]
Ordinary shares, issued							5,425,124
Ordinary shares, offering price					$ 10.48		$ 10.48
Offering costs							$ 690,473
Gross proceeds from preferred shares							56,849,592
Convertible Preferred C Shares [Member]
Offering costs							$ 610,473	$ 6,124
Preferred shares, purchase							927,594
Preferred shares conversion into ordinary shares							(11,501,432)
Convertible Preferred C Shares [Member] \| License Agreement [Member]
Ordinary shares, issued			13,360				13,360
Convertible Preferred C Shares [Member] \| Payments In Lieu [Member]
Ordinary shares, issued							129,419
Shares issued, value							$ 1,356,129

Related Party Transactions - Additional Information (Detail)		3 Months Ended			5 Months Ended	6 Months Ended		12 Months Ended
	Apr. 24, 2015	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2018 USD ($)	Jun. 30, 2018 USD ($) Program	Jun. 30, 2017 USD ($)	Dec. 31, 2017 GBP (£)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 GBP (£)	Dec. 31, 2016 USD ($)	Oct. 31, 2020 GBP (£)	Oct. 31, 2020 USD ($)	Jun. 30, 2018 GBP (£)	Jun. 30, 2018 USD ($)	Oct. 26, 2017 USD ($)
Related Party Transaction [Line Items]
Amount due under services agreement									$ 861,030						$ 0
Related party transaction amounts of work orders issued		$ 139,321		$ 159,041		$ 282,167	$ 306,008
Research and development expenses		7,790,694		5,363,545		14,718,016	10,186,902
Interest expense		9,708		50,894		$ 37,063	59,020
July 2016 Lease [Member]
Related Party Transaction [Line Items]
Operating lease expiration date						Dec. 31, 2021
Operating leases rent expense payment description						The Company records monthly rent expense on a straight-line basis from July 1, 2016 through December 31, 2021.
Deferred rent									231,276						220,722
Operating lease rent expenses		121,890		121,890		$ 243,780	243,780
Aggregate future minimum rental payments under operating lease															1,927,187
Letter of credit outstanding amount															122,866
December 2016 [Member]
Related Party Transaction [Line Items]
Operating lease expiration date						Oct. 31, 2032
Operating leases rent expense payment description						The Company recorded monthly rent expense on a straight-line basis from December 15, 2016 through October 31, 2032.
Operating lease termination date						Mar. 31, 2018
Base rent and management fees					$ 563,507
Promissory note issued																$ 1,442,009
Deferred rent									0						0
Operating lease rent expenses		0		390,903		$ 0	781,806
Promissory note rate of interest						5.00%
Promissory note expiration due date						Dec. 31, 2018
Repayment of promissory note			$ 1,472,433
Interest expense		0				$ 30,424
UCL Consultants Limited [Member] \| Research Agreement [Member]
Related Party Transaction [Line Items]
Amount due under services agreement									775,315						374,873
Related party transaction amounts of work orders issued								£ 241,053	311,000	£ 1,161,149	$ 1,574,000
Agreement termination notice period						30 days
Research and development expenses		183,000		114,000		$ 372,000	222,000
UCL Consultants Limited [Member] \| Manufacturing Agreement [Member]
Related Party Transaction [Line Items]
Amount due under services agreement									$ 2,466,142						374,983
Agreement termination notice period						30 days
Research and development expenses		0		479,494		$ 0	1,042,518
Agreement termination date						2018-01
UCL Consultants Limited [Member] \| License Agreement [Member]
Related Party Transaction [Line Items]
Research and development expenses		0		0		$ 0	0
Number of programs \| Program						8
Potential milestone payment upon achievement of milestone														£ 39,800,000	52,600,000
Annual maintenance fee														£ 50,000	$ 66,000
UCL Consultants Limited [Member] \| Scenario, Forecast [Member] \| Research Agreement [Member]
Related Party Transaction [Line Items]
Future obligations under agreement												£ 797,343	$ 1,052,791
Kadmon [Member] \| Transition Services Agreement with Related Party [Member]
Related Party Transaction [Line Items]
Percentage of administrative fees	7.00%
Services agreement period	3 years
Services termination date	Apr. 24, 2018
Cash payment		$ 145,887		$ 0		$ 1,143,304	$ 275,941

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred Stock, Shares Outstanding	0	5,005,935
Preferred Stock, Liquidation Preference, Value		$ 52,455,700
Common stock, par value	$ 0.00003881	$ 0.00003881
Common stock, shares issued	27,184,132	8,826,190
Common stock, shares outstanding	27,184,132	8,714,563

Organization and Basis of Presentation - Additional Information (Detail)	Jun. 07, 2018 USD ($) $ / shares shares	Mar. 01, 2018 shares	Jun. 30, 2018 USD ($)	Dec. 31, 2017 USD ($)
Schedule Of Description Of Business [Line Items]
Reverse share split ratio	0.257
Cash and cash equivalents			$ 102,060,551	$ 8,548,638
A Ordinary Shares [Member]
Schedule Of Description Of Business [Line Items]
Ordinary shares, issued \| shares	5,000,000	550,162
Ordinary shares, offering price \| $ / shares	$ 15.00
Proceeds from issuance initial public offering net	$ 65,900,000

Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Company's Financial Instruments Carried at Fair Value Measurements (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, net asset (liability)	$ 123,376	$ 123,376
Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, net asset (liability)		2,679,633
Fair Value, Inputs, Level 1 [Member] \| Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, net asset (liability)	$ 123,376	123,376
Fair Value, Inputs, Level 3 [Member] \| Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, net asset (liability)		$ 2,679,633

Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Fair Values of Warrants Estimated by Using Black-Scholes Valuation Model (Detail) - Warrants [Member]		3 Months Ended	12 Months Ended
	Jun. 04, 2018	Mar. 31, 2018	Dec. 31, 2017
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free interest rate	1.77%	1.86%	1.72%
Expected volatility	80.00%	80.00%	80.00%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life	1 day	5 months 15 days	9 months

Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Non-Current Assets by Geographical Area (Detail) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Operation By Geographical [Line Items]
Non current assets	$ 13,691,182	$ 14,379,105
United States
Operation By Geographical [Line Items]
Non current assets	413,481	436,463
United Kingdom
Operation By Geographical [Line Items]
Non current assets	$ 13,277,701	$ 13,942,642

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Clinical Trial Costs	$ 2,297,893	$ 4,859,410
Compensation and Benefits	645,286	2,386,903
Consulting	1,137,547	1,220,477
Rent	128,683	387,267
Professional Fees	733,409	231,923
Interest	30,600	33,437
Travel	135,664
Other	180,179	213,527
Accrued expenses	$ 5,289,261	$ 9,332,944

Share Based Compensation - Schedule of Grant Date Fair Values of the Stock Option Granted Black Scholes Valuation Model (Detail)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Employee and Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.32%
Risk-free interest rate	2.40%
Expected volatility	90.00%
Expected dividend yield	0.00%
Non Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.80%	2.29%
Risk-free interest rate	2.84%	2.31%
Expected volatility	90.00%	80.00%
Expected dividend yield	0.00%	0.00%
Minimum [Member] \| Employee and Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of employee and Board of Directors' options (in years)	5 years 6 months
Minimum [Member] \| Non Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of employee and Board of Directors' options (in years)	7 years 8 months 12 days	8 years 8 months 12 days
Maximum [Member] \| Employee and Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of employee and Board of Directors' options (in years)	6 years 1 month 6 days
Maximum [Member] \| Non Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of employee and Board of Directors' options (in years)	9 years 6 months	9 years 8 months 12 days

Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earning per share, amount	2,485,220	2,274,770
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earning per share, amount		1,584,469
Restricted Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earning per share, amount	870,898	245,828
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earning per share, amount	1,614,322	444,473

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - July 27, 2018 Lease [Member]	Jul. 27, 2018 USD ($) Lease
Subsequent Event [Line Items]
Deferred rent \| $	$ 363,000
Operating lease termination date	May 24, 2027
Number of leases expired	2
Number of new leases	2